Oxygen Delivery Potency of Blood Products
L-TOF: an in vitro framework for comparing oxygen-delivery potency across RBC products and hemoglobin-based formulations.
1. The L-TOF Metric
The L-TOF (Lung-to-Tissue O₂ Flux) metric was introduced in a 2026 peer-reviewed study:
PubMed https://pubmed.ncbi.nlm.nih.gov/42453356/
DOI 10.1016/j.brci.2026.100054
2. HEMOX Analyzer Methodology
The experiments were performed using a HEMOX Analyzer (TCS Scientific Corp). This instrument generated two types of curves for each blood product:
| Curve Type | pH | Simulated Condition |
|---|---|---|
| O₂ Association Curves (OAC) | ~7.6 | Lungs - oxygen loading onto hemoglobin |
| O₂ Dissociation Curves (ODC) | ~6.8 | Tissues - acidic conditions where oxygen is unloaded |
🔗 HEMOX Analyzer TCS Scientific Corp - HEMOX Analyzer
3. Key Findings
3.1 What was compared
The study evaluated fresh and stored blood products and also used artificial whole-blood analogs composed with different hemoglobin-based oxygen carriers. L-TOF integrated matched oxygen association and dissociation behavior across modeled lung-to-tissue oxygen gradients.
| Comparison reported in the study | Modeled equipotent volume |
|---|---|
| Fresh RBCs | 300 ± 0.0 mL |
| Day-42 stored RBC concentrate | 476 ± 21.6 mL |
4. Significance
L-TOF enables a direct, quantitative comparison of oxygen delivery potency between different blood products, providing a much-needed quality metric for transfusion medicine. This tool could help guide more precise transfusion decisions, potentially improving patient outcomes, especially in massive transfusion scenarios.
5. Relevance to BHOC and HBOC Research
- Potency-based evaluation: the study supports evaluating oxygen-delivery potential as a functional property rather than relying on hemoglobin concentration alone.
- Comparative research: L-TOF provides a framework that can be applied to different hemoglobin-based formulations under defined in vitro conditions.
- BHOC relevance: a future BHOC formulation could be tested with this type of metric and compared with RBC products or other oxygen carriers using product-specific data.
- Regulatory caution: L-TOF should currently be treated as a proposed research and quality metric, not as an established regulatory endpoint for HBOC approval.
5.1 Beyond analytical potency
Functional oxygen-delivery assessment should not end with hemoglobin concentration or an oxygen-dissociation curve. Chu et al. extended the analytical question by combining P50, cooperativity, Bohr-effect responsiveness and modeled oxygen-release capacity. Comparative extracellular-hemoglobin studies add further layers: molecular architecture, nitric-oxide interaction, microvascular response and direct evidence of tissue oxygenation should be measured separately rather than assumed from oxygen-binding characteristics alone.
This comparative evidence is not evidence that different extracellular hemoglobins are interchangeable. It supports a product-specific testing sequence in which analytical oxygen handling is connected to vascular behavior, microcirculatory flow and tissue-level oxygen delivery.
6. What This Study Does Not Prove
The paper does not establish clinical superiority of BHOC, Hemopure, Oxyglobin or a generic HBOC class. It does not replace in vivo assessment of vascular response, nitric oxide interaction, microcirculatory flow, oxygen unloading, safety or patient outcomes. Its value here is methodological: it provides a quantitative framework for asking a better oxygen-delivery question.
7. References
- Rogers SC, Brummet M, Tobin KV, Safari Z, Anand A, Bennett D, Adao R, McAslan E, Jacobsen M, Parrish A, Joshi A, Alp E, Zheleznyakova E, Buehler PW, Palmer AF, Salvi T, Beyer G, Khan MA, Renaldo A, Conway A, Rowden T, McGhee W, McCauley S, Sen Gupta A, Bruckman MA, Pawlowski CL, Shea S, Neal MD, Spinella PC, Pan D, Doctor A. Defining and quantifying oxygen delivery potency of blood products. Blood Red Cells & Iron. 2026;2(2):100054. PubMed | DOI
- TCS Scientific Corp. HEMOX Analyzer. https://tcscientific.com/he-mox-analyzer
- Driessen B, Jahr JS, Lurie F, et al. (2001). Effects of hemoglobin-based oxygen carrier on intestinal perfusion. Br J Anaesth.
- Cheung AT, Jahr JS, Driessen B, et al. (2001). The effects of hemoglobin glutamer-200 on the microcirculation. Anesth Analg.
- Chu Z, You G, Li W, et al. Simulated Oxygen Supply Efficiency Assessment to Represent Stored Red Blood Cells Quality. Life. 2026;16(2):205. doi:10.3390/life16020205. PMID:41752843.
- Rousselot M, Delpy E, Drieu La Rochelle C, et al. Arenicola marina extracellular hemoglobin: a new promising blood substitute. Biotechnol J. 2006;1(3):333-345. doi:10.1002/biot.200500049. PMID:16897713.
- Tsai AG, Intaglietta M, Sakai H, Delpy E, Drieu La Rochelle C, Rousselot M, Zal F. Microcirculation and NO-CO studies of a natural extracellular hemoglobin developed for an oxygen therapeutic carrier. Curr Drug Discov Technol. 2012;9(3):166-172. doi:10.2174/157016312802650814. PMID:22564165.
- Le Gall T, Polard V, Rousselot M, et al. In vivo biodistribution and oxygenation potential of a new generation of oxygen carrier. J Biotechnol. 2014;187:1-9. doi:10.1016/j.jbiotec.2014.07.008. PMID:25034433.